肝脏 ›› 2024, Vol. 29 ›› Issue (7): 788-793.

• 肝癌 • 上一篇    下一篇

10例晚期肝癌行介入联合靶免转化治疗序贯手术切除的临床特征分析

段昌虎, 段建峰, 吴林, 邰升, 刘晓晨   

  1. 723000 陕西 西安交通大学医学部附属三二〇一医院肝胆胰脾外科(段昌虎,段建峰,吴林,刘晓晨);150001 黑龙江 哈尔滨医科大学附属第二医院肝胆外科(邰升)
  • 收稿日期:2023-06-30 出版日期:2024-07-31 发布日期:2024-08-27
  • 通讯作者: 刘晓晨,Email:675929952@qq.com
  • 基金资助:
    黑龙江省自然科学基金(H2018025)

An analysis on the efficacy of sequential surgical resection for initial unresectable hepatocellular carcinoma treated with interventional therapy combined with targeted immunotherapy

DUAN Chang-hu, DUAN Jian-feng, WU Lin, TAI Sheng, LIU Xiao-chen   

  1. 1. Department of Hepatobiliary Surgery, 3201 Hospital of Xi'an Jiaotong University Health Science Center,Hanzhong 723000, China;
    2. Department of Hepatobiliary Surgery, the 2nd Affiliated Hospital of Harbin Medical University, Heilongjiang 150086, China
  • Received:2023-06-30 Online:2024-07-31 Published:2024-08-27
  • Contact: LIU Xiao-chen,Email:675929952@qq.com

摘要: 目的 评估晚期肝细胞癌行介入联合靶向及免疫转化治疗后序贯手术切除的临床特征,探讨其安全性及有效性。方法 回顾性收集并分析西安交通大学附属三二〇一医院自2021年6月—2023年5月期间收治的10例初始不可切除的晚期肝癌患者的临床数据。结果 10例患者中,8例为男性,2例为女性,中位年龄55(33~72)岁;Child-Pugh分级标准A级6例,B级4例;CNLC分期Ⅱb期4例,Ⅲa期6例;ECOG ps评分均≤1分;6 例合并肝硬化,4例无肝硬化;合并门静脉癌栓6例,无门静脉癌栓者4例;转化治疗前最大肿瘤直径13 cm,治疗前AFP>400 ng/mL者7例,AFP<400 ng/mL者3例;乙肝患者7例,丙肝2例, 1 例无肝炎;转化治疗方案:TACE+靶向+免疫方案治疗的有5例、HAIC+靶向+免疫方案5例,治疗过程中发生高血压4例、乏力2例、腹泻1例;中位转化时间为4月;转化治疗后术前的肿瘤最大直径为8.8 cm,转化治疗后术前的中位AFP 水平 17.2 ng/mL,术前影像学评估(mRECIST)CR 4例,PR 3例,SD 3例;术前 PS 评分均≤1 分。转化后行手术切除:3例行肝部分切除,7例行半肝切除;经腹腔镜手术7例,开腹手术3例。中位手术时间240 min,中位术中出血量400 mL,术后中位住院天数为8 d,术后中位拔除引流管的时间为7 d。术后病理结果pCR 3例,pPR有7 例,MVI分级M0有 8例,M1有2例,术后切缘均为阴性。术后出现腹水1例,胆漏 1例,余无明显术后并发症。术后中位随访时间8个月,1例出现复发,随访期间无患者死亡。结论 部分晚期肝细胞癌患者行介入等局部治疗联合靶向及免疫转化治疗后序贯手术切除是安全有效的。

关键词: 晚期肝癌, 转化治疗, 靶免联合, 介入治疗, 外科手术, 临床特征

Abstract: Objective To evaluate the clinical efficacy and analyze of sequential surgical resection for initial unresectable hepatocellular carcinoma treated with interventional therapy combined with targeted immunotherapy. Methods The clinical data from 10 patients with initial unresectable hepatocellular carcinoma admitted to the 3201 hospital of Xi'an Jiaotong University Health Science Center from June 2021 to May 2023 were retrospectively collected and analysed. Results Of the 10 patients, 8 were male and 2 was female, with a median age of 55 years (33~72 years); there were 6 cases with Child Pugh grade A and 4 cases with grade B; 4 cases with CNLC stage IIb and 6 cases with IIIa; The PS scores of all patients were ≤1; there were 6 cases with cirrhosis and 4 cases without cirrhosis; 6 cases with portal vein cancer thrombus and 4 cases without portal vein cancer thrombus;the maximum tumor diameter before transformation therapy was 13 cm, with 7 cases having AFP>400 ng/mL and 3 cases having AFP<400 ng/mL before treatment; There were 7 cases with hepatitis B, 2 cases with hepatitis C and 1 case without viral hepatitis; The conversion treatment programmes included: 1) TACE combined with anti-angiogenic targeting drugs and immune checkpoint inhibitors in 5 cases, 2) HAIC combined with anti-angiogenic targeting drugs and immune checkpoint inhibitors in 5 cases. During the treatment, there were 4 cases with hypertension, 2 cases with fatigue, and 1 case with diarrhea; the median conversion time were 4 months. The maximum diameter of the tumor after conversion therapy before surgery was 8.8 cm, and the median AFP level after conversion therapy before surgery was 17.2 g/mL, In preoperative imaging assessment (mRECIST), there wereCR in 4 cases, PR in 3 cases, SD in 3 cases; preoperative PS score ≤1 point. After therapy, surgical resection was performed: 3 cases underwent partial hepatectomy, 7 cases underwent semi-hepatic resection; 7 cases underwent laparoscopic surgery, and 3 cases underwent open surgery; The median surgical time was 240 minutes. The median intraoperative blood loss was 400 mL.The median postoperative hospital stay was 8 days, and the median postoperative drainage tube removal time was 7 days. The postoperative pathological results shown that there were 3 cases of pCR, 7 cases of pPR, 8 cases of MVI grade M0, 2 cases of M1 , no case of positive resection margin. Postoperative ascites occurred in 1 case, bile leakage in 1 case, and there were no significant postoperative complications. The median follow-up time after surgery was 8 months, with 1 case experiencing recurrence and no patient died during follow-up. Conclusion Sequential surgical resection for initial unresectable hepatocellular carcinoma treated with interventional therapy combined with targeted immunotherapy is effective and safe.

Key words: Unresectable hepatocellular carcinoma, Conversion therapy, Targeted combined immunotherapy, Interventional therapy, Hepatectomy